Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846312 · ClinicalTrials.gov registry record
An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 40
- Enrollment target
NCT01846312 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 40 participants.
The verdict
NCT01846312 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study is conducted in the United States of America (USA). The aim of the study is to assess longitudinal variation of immune biomarkers in subjects at risk for development of type 1 diabetes (T1D).
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846312
The ClinicalTrials.gov registry entry for NCT01846312 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT01846312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01846312 about?
NCT01846312 is a clinical study titled "An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes". This study is conducted in the United States of America (USA). The aim of the study is to assess longitudinal variation of immune biomarkers in subjects at risk for development of type 1 diabetes (T1D).
What is the current status of trial NCT01846312?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2013-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01846312?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT01846312?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.